by Dennis Crouch The Federal Circuit recently affirmed the invalidity of several Purdue Pharma patents related to abuse-deterrent and low-impurity formulations of OxyContin. Purdue Pharma L.P. v. Accord Healthcare, Inc., No. 2023-1953 (Fed. Cir. Dec. 30, 2024).  Although non-precedential, the appeal addresses three significant legal questions in obviousness jurisprudence: (1) The consideration given to discovering … Continue reading Federal Circuit Affirms Invalidity of Purdue’s OxyContin Patents